Quanterix Receives $46,000,000 Series D Funding

  • Feed Type
  • Date
    3/23/2016
  • Company Name
    Quanterix
  • Mailing Address
    113 Hartwell Avenue Lexington, MA 02421 USA
  • Company Description
    At Quanterix, our principal focus is to improve human health by providing physicians, drug developers, and researchers with the ability to detect and analyze important biomolecules within complex biological samples at the level of single molecules. The company was founded in June 2007 by successful entrepreneurs Dr. David Walt and Dr. Nick Naclerio.
  • Website
    http://www.quanterix.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $46,000,000
  • Transaction Round
    Series D
  • Proceeds Purposes
    This infusion of capital will allow Quanterix to build on the significant growth realized in the last two years. Proceeds will be used to develop desk-top instruments, expand the assay menu for protein and nucleic acid biomarkers, bolster the global channel to market and enable new, pivotal medical studies to be performed with Quanterix’ game changing technology, transforming life science research and diagnostics.
  • M&A Terms
  • Venture Investor
    ARCH Venture Partners
  • Venture Investor
    Cormorant Asset Management
  • Venture Investor
    Bain Capital Ventures
  • Venture Investor
    Investor
  • Venture Investor
    Hercules Technology Growth Capital

Trending on Xconomy